Radiopharmaceutical · Cytotoxic, directed at bone · developed by Telix Pharmaceuticals Pty
Samarium Sm 153-DOTMP is a radiopharmaceutical composed of the beta- and gamma-emitting radioisotope samarium Sm 153 conjugated to the phosphonic acid chelator DOTMP. The DOTMP moiety targets growing bone, selectively delivering samarium-mediated cytotoxic radiation to bone tumors and metastases to destroy them and mitigate pain.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07197645 | Phase 1 | Bone Pain | Recruiting | TLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bone Metastases in Subjects With Advanced CancerBone PainMetastatic Bone Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.
See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLX catalysts and pipeline →